BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27922540)

  • 1. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.
    Zhu X; Liao C; Penney BC; Li F; Ferguson MK; Simon CA; Wu T; Liu H; Pu Y
    Nucl Med Commun; 2017 Feb; 38(2):185-192. PubMed ID: 27922540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
    Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
    Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.
    Zhang H; Wroblewski K; Appelbaum D; Pu Y
    Int J Comput Assist Radiol Surg; 2013 Mar; 8(2):181-91. PubMed ID: 22644386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation.
    Dashevsky BZ; Zhang C; Yan L; Yuan C; Xiong L; Liu Y; Liu H; Kong FS; Pu Y
    Eur J Hybrid Imaging; 2017; 1(1):8. PubMed ID: 29782599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
    Finkle JH; Penney BC; Pu Y
    Lung Cancer; 2018 Sep; 123():136-141. PubMed ID: 30089584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic tumor burden on postsurgical PET/CT predicts survival of patients with gastric cancer.
    Sun G; Cheng C; Li X; Wang T; Yang J; Li D
    Cancer Imaging; 2019 Mar; 19(1):18. PubMed ID: 30902116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new PET/CT volumetric prognostic index for non-small cell lung cancer.
    Zhang H; Wroblewski K; Jiang Y; Penney BC; Appelbaum D; Simon CA; Salgia R; Pu Y
    Lung Cancer; 2015 Jul; 89(1):43-9. PubMed ID: 25936471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
    Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
    Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy.
    Evangelista L; Cuppari L; Menis J; Bonanno L; Reccia P; Frega S; Pasello G
    Nucl Med Commun; 2019 Aug; 40(8):802-807. PubMed ID: 31045745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.
    Pu Y; Zhang JX; Liu H; Appelbaum D; Meng J; Penney BC
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2079-2092. PubMed ID: 29882161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.
    Finkle JH; Jo SY; Ferguson MK; Liu HY; Zhang C; Zhu X; Yuan C; Pu Y
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1275-1284. PubMed ID: 28265739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18 F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy.
    Feng Y; Wang P; Chen Y; Dai W
    Nucl Med Commun; 2023 Oct; 44(10):900-909. PubMed ID: 37503694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic active tumour volume quantified on [
    Rocha ALG; da Conceição MAM; da Cunha Sequeira Mano FXP; Martins HC; Costa GMLM; Dos Santos Oliveiros Paiva BCB; Lapa PAA
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3601-3611. PubMed ID: 34570257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of metabolic tumor volume of pretreatment
    Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
    BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer.
    Sharma A; Mohan A; Bhalla AS; Vishnubhatla S; Pandey AK; Bal CS; Kumar R
    Nucl Med Commun; 2017 Oct; 38(10):858-867. PubMed ID: 28817456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.